The executive team

ResMed’s executive team is committed to the highest standards of ethics and professional integrity, translating to great partnerships with our customers, our suppliers, and with our global ResMed team. Our friendly, smart and dynamic executive team is dedicated to providing the right solutions with the right results, every time.

 

 

Michael J. Farrell

Chief Executive Officer

Michael “Mick” Farrell is the CEO for ResMed and has held the role since March 2013. Prior to that appointment, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously senior vice president of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development at the company.

Before joining ResMed in 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals, and metals manufacturing at Arthur D. Little, Genzyme Corporation (now part of Sanofi), The Dow Chemical Company, and BHP Billiton.

Mr. Farrell serves on the board of directors of Zimmer Biomet (NYSE: ZBH), a multi-billion dollar public company that provides implantable musculoskeletal medical devices for patients globally.  Mr. Farrell is a member of the compensation and management development committee as well as the research, innovation and technology committee at Zimmer Biomet.  Mr. Farrell serves on the ResMed board of directors as well as on the board of directors of the Advanced Medical Technology Association (AdvaMed), based in Washington, DC. Mr. Farrell volunteers as a trustee for two non-profit organizations, the La Jolla Playhouse and the Museum of Man, in his home town of San Diego, California.

Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.


Robert Douglas

President and Chief Operating Officer

Robert Douglas added president to his role of chief operating officer in March 2013 and, together with ResMed chief executive officer, Mick Farrell, holds full operational responsibility for ResMed and its subsidiaries. Mr. Douglas has served as chief operating officer since September 2011. His former roles with the company include chief operating officer of Asia Pacific and global supply chain from June 2008 through September 2011, responsible for the region’s commercial distribution and sales operations, as well as global manufacturing; Sydney chief operating officer from November 2005 through June 2008, responsible for the company’s manufacturing and research and development; vice president of operations from 2003 to 2005, responsible for the company’s manufacturing; and vice president of ResMed’s respiratory and cardiac business from 2002 to 2003.

Mr. Douglas first joined ResMed in 2001 as vice president of corporate marketing.

Mr. Douglas has a Master of Business Administration from Macquarie University, a Bachelor’s degree in electrical engineering with first-class honors, and a Bachelor of Science in computer sciences from the University of New South Wales, Sydney.


David Pendarvis

Chief Administrative Officer, Global General Counsel

David Pendarvis was appointed interim President for EMEA and Japan in March 2017. He has served as both Chief Administrative Officer and Global General Counsel since May 2011. Mr. Pendarvis joined ResMed as global general counsel in September 2002, and has been corporate secretary since February 2003. From February 2005 to May 2011, he served as senior vice president of Organizational Development.

Before joining ResMed, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP from September 2000 until September 2002, where he specialized in intellectual property and general business litigation. From 1986 to 2000, he was a partner with Gibson, Dunn & Crutcher LLP. From 1984 to 1986, he was a law clerk to the Hon. J. Lawrence Irving, U.S. District Judge, Southern District of California. He is also a director on the Board of Sequenom, Inc.

Mr. Pendarvis holds a Bachelor of Arts from Rice University; a Juris Doctor (J.D.), cum laude, from the University of Texas School of Law; and a Master of Science in Executive Leadership from the University of San Diego.


Brett Sandercock

Chief Financial Officer

Brett Sandercock has been chief financial officer since January 2006. Previously, he served as vice president of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to November 2004.

Before joining ResMed, Mr. Sandercock was a manager of financial accounting and group reporting at Norton Abrasives, a division of the French multi-national, Saint Gobain, from March 1996 to August 1998. He also held finance and accounting roles from November 1994 to March 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients predominantly focused on distribution and manufacturing, financial services and technology.

Brett holds a Bachelor degree in economics from Macquarie University in Sydney, and is a certified chartered accountant.


Jim Hollingshead

President, Sleep and Respiratory Care Business

Jim Hollingshead was appointed president of ResMed’s Sleep and Respiratory Care business in June 2020, an extension of his role as president of Sleep, which he’s held since July 2017. He previously served as president of the company’s Americas region, beginning in March 2013. He joined the company in 2010 as vice president of Strategy and Business Development. In 2011, his role was expanded to include the leadership of ResMed’s Ventures and Initiatives unit, responsible for growing early-stage businesses.

Before joining ResMed, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that, he was West Coast managing partner for Monitor Group, a leading global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world and successfully launched and ran three different practices, including a London-based pan-European marketing strategy practice.

Mr. Hollingshead holds a Bachelor of Arts in history and international relations with Highest Distinction from Stanford University, and a master’s and Ph.D. in political science from the University of California at Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.


Katrin Pucknat

Chief Executive Officer, ResMed Healthcare, Germany

Katrin Pucknat was appointed Chief Executive Officer of ResMed Healthcare, Germany during July 2016. ResMed Healthcare is a German homecare provider which services patients with sleep-disordered breathing, COPD and other chronic respiratory diseases.

Ms. Pucknat joined ResMed in 2010 and has served in a variety of senior roles. Immediately prior to her current role, Katrin served as vice president of business transformation and had responsibility within ResMed Healthcare for patient services, TPR, field offices and the consumer business. Prior to that role, she was the director of marketing for ResMed’s sleep-disordered breathing business in Europe.

Before joining ResMed, Ms. Pucknat held various senior executive global marketing roles in the United States and Europe.  She has almost 20 years of experience in the medical device segment, with particular focus on the functions of marketing, communications, business innovation and business development.

While gaining her broad experience based in the U.S. market, Ms. Pucknat earned a Bachelor of Business and Marketing degree from the University of Phoenix.  She is based at the headquarters of our ResMed Healthcare business in Munich, Germany.


Justin Leong

President, Asia and Latin America

Justin Leong became senior vice president of ResMed’s growth markets in Asia, including China and India, in May 2016. He was previously general manager of Greater China from 2015 to 2016, and vice president of Global Strategy from 2013 to 2016, based in Sydney.

Prior to joining ResMed, Mr. Leong was a director of the London-based investment firm HgCapital from 2006 to 2012. In this role, Mr. Leong was responsible for acquisitions and portfolio management, and he served on the board of directors of several European healthcare companies. From 1999 to 2004, Mr. Leong was a management consultant with Bain & Co. in Sydney, Boston and New York where he advised clients on growth strategies, operational improvement projects and mergers & acquisitions.

Mr. Leong holds a Bachelor of Commerce and Bachelor of Laws from the University of New South Wales, and an M.B.A. from Harvard Business School.


 

Vered Keisar

Chief People Officer

Vered Keisar was appointed ResMed Chief People Officer in March 2021, responsible for driving the company’s global culture and People strategy. She previously served as vice president and General Counsel for ResMed’s Asia and Latin America regions. Vered has over 25 years of broad industry experience ranging from healthcare and pharmaceuticals to defense and insurance. Before joining ResMed in 2012, she worked in leading law firms in the UK, Australia, Japan, and Israel.

Vered is qualified to practice law in England and Wales, Australia, and Israel. She has an MBA from the Sydney Graduate School of Management, a Diploma of Laws in European Competition Law from King’s College in London, and a Bachelor of Laws from the College of Management Academic Studies in Israel.

From 2016 to 2020, Vered was the elected chairperson of the Australian Diversity and Inclusion Committee for the Association of Corporate Counsel, the world’s largest organization dedicated to in-house counsel, with more than 45,000 members in 85 countries.

Since 2012, Vered has been an ambassador and speaker for the Australian National Breast Cancer Foundation.

Hemanth Reddy

Chief Strategy Officer

Hemanth Reddy was appointed ResMed’s chief strategy officer in September 2013, responsible for the company’s global corporate strategy and corporate development functions.

Prior to joining ResMed, Hemanth was a strategy consultant for 14 years, advising on a range of issues including corporate strategy, business unit strategy, portfolio strategy, and inorganic growth strategy across consumer products, high tech, biotech and other industries. He was most recently a principal with Monitor Deloitte, Deloitte Consulting’s Strategy practice, co-leading its San Francisco office. Prior to Deloitte, he was a partner with Monitor Group where he co-led corporate finance activities in North America and shared leadership responsibility for Monitor’s Mergers & Acquisitions advisory practice. Before Monitor Group, he was an investment banker with Donaldson, Lufkin & Jenrette (DLJ) in New York, where he advised clients in structuring and executing debt and equity offerings, as well as private equity transactions.

Hemanth holds a Master of Business Administration in Finance, Strategy and Marketing from Northwestern University’s Kellogg School of Management and a bachelor’s in computer science from Cornell University’s College of Engineering.


Dr. Carlos M. Nunez, M.D.

Chief Medical Officer

Dr. Carlos Nunez M.D. was appointed Chief Medical Officer in January 2017. Prior to joining ResMed, Dr. Nunez was senior vice president of medical affairs at Becton, Dickinson and Company and led the office of science, medicine and technology for its largest division. Before that, Dr. Nunez was chief medical officer at CareFusion, where he built and led a global team which provided medical oversight for all businesses and functions of the company.

From 2000 to 2011, he was the Chief Physician Executive at Picis, Inc., an industry-leading medical informatics company, which became part of the Optum division of UnitedHealth Group. At Picis/Optum, Carlos provided medical leadership as well as clinical direction for corporate strategy, marketing, product development, sales, implementation and customer relations for global markets.

Dr. Nunez received his Medical Doctor (M.D.) degree from the University of Miami School of Medicine, where he also completed his postgraduate training in anaesthesiology, critical care medicine and clinical research.

Before beginning his career in the MedTech industry, Carlos was a practicing anaesthesiologist; intensivist and hospitalist; director of critical care research, informatics and analytics; and the Duke University educational affiliation at Carolinas Medical Center Northeast.


Bobby Ghoshal

Chief Technology Officer

Bobby Ghoshal was appointed President of ResMed’s SaaS business in August 2021, in addition to his role as chief technology officer (CTO), which he’s held since April 2018. He previously served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care: delivering improved clinical and business performance for homecare customers. Prior to that Bobby led the information technology function for the US, Canada, and Latin America commercial teams, driving adoption of digital platforms and data analytics across the enterprise.

Bobby has more than 25 years’ experience in technology across multiple industries including finance, semiconductors and healthcare, working for companies including Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Bobby has helped build and lead high-performance teams in information technology, semiconductor innovation, digital and business strategy, information security, advanced analytics, operations and customer care.

Bobby holds a Master of Business Administration degree from Arizona State University and a bachelor’s degree in electronics engineering and telecommunications from the National Institute of Technology (NIT) in Calicut, India.


Andrew Price

President, Global Operations

Andrew Price was appointed president of ResMed’s global operations in July 2017. He joined ResMed in 1999, most recently serving as president of Innovation and Operations. He also served in a variety of senior leadership roles for the company, including senior vice president of global manufacturing and logistics, vice president of marketing for Asia Pacific, and vice president of product development and marketing in the company’s Sleep-disordered Breathing business unit. He joined ResMed as a design engineer and holds a number of patents granted worldwide.

Prior to joining ResMed, Andrew held product development roles at Sunbeam, a consumer appliances manufacturer, and Aristocrat Leisure Industries, one of the world’s leading providers of gaming solutions.

Andrew graduated from the Advanced Management Program (AMP) at the INSEAD International Business School in Singapore, holds a bachelor’s degree with honors in industrial design from the University of Technology, Sydney, and is a Lean Six Sigma Green Belt.